For more information on this report please contact ediz.ibrahim@visiongain.com (+44 (0) 2075499976) or refer to our website: http://www.visiongain.com/Report/1111/The-Prostate-Cancer-Therapeutics-Market-2013-2023

1. ©notice
This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of vision-
gain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each pur-
chase and single copy is for personal use only.
The Prostate Cancer Therapeutics
Market 2013-2023

2. www.visiongain.com
Contents
1.1 Overview of Prostate Cancer Therapeutics Market
1.2 Overview of Findings
1.3 Chapter Outline
1.4 Research and Analysis Method
1.5 Glossary of Terms Relating to Prostate Cancer Therapeutics Market
2.1 What is Cancer?
2.2 Phenotypic Characteristics of Cancer Cells
2.2.1 Uncontrollable Growth
2.2.2 Loss of Apoptosis Pathways
2.2.3 Lack Differentiation
2.2.4 Increased Angiogenesis
2.2.5 Potential for Metastasis
2.2.6 Genetic Instability
2.3 What Causes Cancer?
2.4 Worldwide Prevalence of Cancer: A Global Picture
2.5 What is Prostate Cancer?
2.6 Worldwide Prevalence of Prostate Cancer: Rapid Global Growth
2.7 Risk Factors for Prostate Cancer
2.8 How is Prostate Cancer Diagnosed?
2.8.1 PSA Testing
2.8.2 Digital Rectal Examination Testing
1. Executive Summary
2. Introduction

3. www.visiongain.com
Contents
2.8.3 Newly Approved Tests May Improve Diagnosis
2.9 Treatment Sequence for Prostate Cancer
2.9.1 Localised Prostate Cancer: Surgery/Radiation is Most Preferred
2.9.1.1 Brachytherapy
2.9.1.2 Radical Prostatectomy
2.9.1.3 External Beam Radiation Therapy
2.9.1.4 Cryotherapy
2.9.1.5 High-Intensity Focussed Ultrasound (HIFU)
2.9.2 Androgen Deprivation Therapy
2.9.3 Non-Metastatic CRPC: Ketoconazole and Anti-Androgens
2.9.4 Metastatic CRPC: Provenge Loosing its Dominance
2.9.5 First Line Chemotherapy: Docetaxel is a Standard Treatment
2.9.6 Post Docetaxel Therapy: Four FDA Approved Drugs
2.9.7 Second Line Chemotherapy: Jevtana Approved in 2010
3.1 The Global Prostate Cancer Therapeutics Market, 2012
3.2 The Global Prostate Cancer Therapeutics Market Forecast, 2012-2017
3.3 The Global Prostate Cancer Therapeutics Market Forecast, 2017-2023
3.4 The Global Prostate Cancer Therapeutics Market: Drivers and Restraints 2013-2023
4.1 The Prostate Cancer Drugs Market is Highly Competitive
4.2 The Prostate Cancer Drugs Market, 2012
4.3 The Prostate Cancer Drugs Market Forecast, 2012-2017
3. The Prostate Cancer Therapeutics Market 2013-2023
4. The Prostate Cancer Drugs Market 2013-2023

4. www.visiongain.com
Contents
4.4 The Prostate Cancer Drugs Market Forecast, 2017-2023
4.5 Leading Prostate Cancer Drugs: Market Prospects, 2012-2023
4.5.1 Zytiga (Johnson &Johnson/Janssen)
4.5.1.1 Zytiga Sales, 2012
4.5.1.2 Zytiga Sales Forecast, 2012-2023
4.5.2 Lupron (AbbVie)
4.5.2.1 Lupron Sales, 2012
4.5.2.2 Lupron Sales Forecast, 2012-2023
4.5.3 Zoladex (AstraZeneca)
4.5.3.1 Zoladex Sales, 2012
4.5.3.2 Zoladex Sales Forecast, 2012-2023
4.5.4 Casodex (AstraZeneca)
4.5.4.1 Casodex Sales, 2012
4.5.4.2 Casodex Sales Forecast, 2012-2023
4.5.5 Taxotere (Sanofi)
4.5.5.1 Taxotere Sales, 2012
4.5.5.2 Taxotere Sales Forecast, 2012-2023
4.5.6 Provenge (Dendreon Corporation)
4.5.6.1 Provenge Sales, 2012
4.5.6.2 Provenge Sales Forecast, 2012-2023
4.5.7 Jevtana (Sanofi)
4.5.7.1 Jevtana Sales, 2012
4.5.7.2 Jevtana Sales Forecast, 2012-2023
4.5.8 Xtandi (Medivation/Astellas Pharma)
4.5.8.1 Xtandi Sales, 2012

5. www.visiongain.com
Contents
4.5.8.2 Xtandi Sales Forecasts, 2012-2023
4.6 Late Stage Clinical Trial Failures, 2013
4.6.1 Aflibercept (Zaltrap, Regeneron/Sanofi)
4.6.2 Dasatinib (Sprycel, Bristol Myers Squibb)
4.6.3 Lenalidomide (Revlimid, Celgene)
4.6.4 TAK-700 (Orteronel, Takeda)
4.7 Prostate Cancer Drugs Pipeline, 2013
4.7.1 Yervoy (Bristol Myers Squibb)
4.7.2 Cabozantinib (Exelixis)
4.7.3 Tasquinimod (Active Biotech AB/Ipsen)
4.7.4 Prostvac (Bavarian Nordic)
4.7.5 Custirsen (OncoGenex Pharmaceuticals)
4.7.6 MDV-3100 (Medivation/Astellas Pharma)
4.7.7 ProstAtak (Advantagene)
4.7.8 DCVax-Prostate (NorthWest Biotherapeutics)
4.7.9 GVAX Prostate (Aduro Biotech)
4.7.10 GDC-0980 (Roche)
4.7.11 PSMA ADC (Progenics Pharmaceuticals)
4.7.12 EMD-525797 (EMD Sereno)
4.7.13 Galeterone (Tokai Pharmaceuticals)
4.7.14 OGX-427 (OncoGenex Pharmaceuticals)
4.7.15 ARN-509 (Johnson & Johnson)
4.7.16 MGAH22 (MacroGenics)
4.7.17 RG7450 (Roche)
4.7.18 ASG-5ME (Agensys/Seattle Genetics)

6. www.visiongain.com
Contents
4.7.19 BAY2010112 (Bayer Pharmaceuticals)
4.7.20 GDC-0068 (Roche)
4.8 Leading Companies in the Prostate Cancer Drugs Market, 2013
4.8.1 Johnson & Johnson (J&J)
4.8.1.1 Sales and Performance Analysis, 2012
4.8.1.2 Pharmaceutical Segment Sales Analysis, 2012
4.8.1.3 Pharmaceutical Segment R&D Performance Analysis, 2012
4.8.1.4 Recent M&A Activity
4.8.1.4.1 Acquisition of Aragon Pharmaceuticals
4.8.2 AstraZeneca
4.8.2.1 Sales and Performance Analysis, 2012
4.8.2.2 R&D Performance Analysis, 2012
4.8.3 Sanofi
4.8.3.1 Sales and Performance Analysis, 2012
4.8.3.2 Oncology Sales and Performance Analysis, 2012
4.8.3.3 R&D Performance Analysis, 2012
4.8.3.4 Recent M&A Activity
5.1 The Prostate Cancer Devices Market, 2012
5.2 Prostate Cancer Devices Market Forecast, 2012-2017
5.3 Prostate Cancer Devices Market Forecast, 2017-2023
5.4 Brachytherapy Market 2012-2023: Driven By Physician Adoption
5.5 Radical Prostatectomy Market 2012-2023: Higher Patient Preference
5.5.1 Intuitive Surgical’s da Vinci Surgical System will Drive Market Growth
5. The Prostate Cancer Devices Market 2013-2023

7. www.visiongain.com
Contents
5.6 External Beam Radiation Therapy Market 2012-2023
5.7 Cryotherapy Market 2012-2023: Fastest Growing Market
5.8 HIFU Market 2012-2023: Driven by Demand for Non-Invasive Surgery
5.9 Leading Companies in the Prostate Cancer Devices Market, 2012
5.9.1 Varian Medical Systems
5.9.1.1 Sales and Performance Analysis, 2012
5.9.1.2 Oncology Systems Sales Analysis, 2012
5.9.1.3 R&D Performance Analysis, 2012
5.9.1.4 Key Oncology Products, 2013
5.9.1.5 Varian and Siemens Partnership: Shaping the Future of Cancer Care
5.9.2 Elekta
5.9.2.1 Sales and Performance Analysis, 2012
5.9.2.2 Elekta and Philips Establish Research Consortium
6.1 Regional Breakdown of the Prostate Cancer Therapeutics Market, 2012
6.2 The Prostate Cancer Therapeutics Market: Regional Forecast 2012-2023
6.3 The US Market 2012-2023: Largest National Market
6.4 The EU5 Market 2012-2023
6.4.1 Germany and France 2012-2023: Two Largest EU Markets
6.4.2 The UK Market 2012-2023: Budgetary Constraints
6.4.3 The Spanish Market 2012-2023: Facing Cost Containment Measures
6.4.4 The Italian Market 2012-2023: Slow Growth Owing to Economic Crisis
6.5 The Japanese Market 2012-2023: Driven by Aging Population
6.6 The BRIC Nations 2012-2023: Strong Potential for Growth
6. The Leading National Markets 2013-2023

8. www.visiongain.com
Contents
6.6.1 The Chinese Market 2012-2023: Highest Revenue Generator Among BRIC Nations
6.6.2 The Indian Market 2012-2023: Lucrative Opportunity for Growth
6.6.3 The Russian Market 2012-2023: Rising Incidence of Cancer
6.6.4 The Brazilian Market 2012-2023: BRIC’s Smallest Market
7.1 SWOT Analysis, 2013-2023
7.2 Strengths
7.2.1 Prostate Cancer is a High Profile Disease
7.2.2 Rapidly Expanding Aging Population
7.2.3 Strong R&D Pipeline
7.2.4 Use of Off-Label Drugs are Common
7.3 Weaknesses
7.3.1 Prostate Cancer Drugs are Expensive
7.3.2 R&D Failures in Late Stage Development
7.3.3 Impact of Economic Downturn on Healthcare Spending
7.4 Opportunities
7.4.1 Rising Incidence of Cancer
7.4.2 Emerging National Markets will Drive Growth
7.4.3 Stem Cells Offer Promise
7.4.4 Advances in Diagnostic Technologies: CTC as a Biomarker
7.5 Threats
7.5.1 Concerns about Efficacy and Toxicity of Drugs
7. Qualitative Analysis of the Prostate Cancer Therapeutics Market
2013-2023

9. www.visiongain.com
Contents
7.5.2 Who will pay for the High Cost of Drugs and Devices?
7.5.3 Governments Cut Down Healthcare Spending
7.5.4 Increase in Generic Competition
7.6 Porter’s Five Force Analysis
7.6.1 Rivalry Among Competitors
7.6.2 Threat of New Entrants
7.6.3 Power of Suppliers
7.6.4 Power of Buyers
7.6.5 Threat of Substitutes
8.1 Interview with Dr. Deepak Batura, Consultant Urological Surgeon
8.1.1 Views on Early-Stage Prostate Cancer Treatment
8.1.2 Advantages of Using Robots for Prostatectomy
8.1.3 Potential of HIFU to Replace Conventional Therapies
8.1.4 Does Eating Right Reduce Prostate Cancer Risk?
8.1.5 Outlook for Future
9.1 The Prostate Cancer Therapeutics Market, 2012-2023
9.2 The US Will Remain the Largest National Market during 2012-2023
9.3 Concluding Remarks
8. Expert Opinion
9. Conclusions

10. www.visiongain.com
Contents
Table 2.1 PSA Testing: Benefits and Limitations, 2013
Table 2.2 New Prostate Cancer Diagnostic Tests in Market, 2013
Table 3.1 The Global Prostate Cancer Therapeutics Market: Revenue ($bn) and Market Shares
(%) by Segment, 2012
Table 3.2 The Global Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), AGR (%),
CAGR (%), 2012-2017
Table 3.3 The Global Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), AGR (%),
CAGR (%), 2017-2023
Table 3.4 The Global Prostate Cancer Therapeutics Market: Drivers and Restraints 2013-2023
Table 4.1 The Prostate Cancer Drugs Market: Revenue ($bn) and Market Shares (%) by Leading
Drugs, 2012
Table 4.2 The Prostate Cancer Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%),
2012-2017
Table 4.3 The Prostate Cancer Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%),
2017- 2023
Table 4.4 Zytiga: Revenue Forecast ($bn), AGR (%), CAGR (%), 2012-2023
Table 4.5 Lupron: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023
Table 4.6 Zoladex: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023
Table 4.7 Casodex: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023
Table 4.8 Taxotere : Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023
Table 4.9 Provenge: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023
Table 4.10 Jevtana: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023
Table 4.11 Xtandi: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023
Table 4.12 Negative Phase III Trials in which Targeted Drug was Added to Docetaxel, 2013
List of Tables

11. www.visiongain.com
Contents
Table 4.13 Key Drugs in Phase III Clinical Trials, 2013
Table 4.14 Key Drugs in Phase II Clinical Trials, 2013
Table 4.15 Key Drugs in Phase I Clinical Trials, 2013
Table 4.16 Johnson & Johnson: Revenue ($bn) and Revenue Shares (%) by Segment, 2012
Table 4.17 Johnson & Johnson: Pharmaceutical Revenue ($bn) and Revenue Shares (%) by
Segment, 2012
Table 4.18 Johnson & Johnson: Oncology Drugs Historical Sales ($m), 2010-2012
Table 4.19 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($bn) and R&D
Expenses as Percentage of Segment Revenue (%), 2010-2012
Table 4.20 AstraZeneca: Revenue ($bn) and Revenue Shares (%) by Segment, 2012
Table 4.21 AstraZeneca: Anti-Cancer Drugs Revenue ($bn), Change in Revenue (%) and
Revenue Shares (%), 2011-2012
Table 4.22 Selected Drugs from AstraZeneca Oncology Pipeline, 2012
Table 4.23 Sanofi: Net Sales ($bn) and Net Sales Shares (%) by Segment, 2012
Table 4.24 Sanofi: Net Sales ($bn) and Net Sales Shares (%) by Region, 2012
Table 4.25 Sanofi: Oncology Sales ($bn) by Product, 2012
Table 4.26 Sanofi: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Revenue
(%), 2010-2012
Table 5.1 The Prostate Cancer Devices Market: Revenue ($m) and Market Shares (%) by
Segment, 2012
Table 5.2 The Prostate Cancer Devices Market Forecast: Revenue ($m), AGR (%), CAGR (%) by
Segment, 2012-2017
Table 5.3 The Prostate Cancer Devices Market Forecast: Revenue ($m), AGR (%), CAGR (%) by
Segment, 2017-2023
Table 5.4 Brachytherapy Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023

12. www.visiongain.com
Contents
Table 5.5 Radical Prostatectomy Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-
2023
Table 5.6 External Beam Radiation Therapy Market: Revenue Forecast ($m), AGR (%) CAGR
(%), 2012-2023
Table 5.7 Cryotherapy Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023
Table 5.8 HIFU Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023
Table 5.9 Varian Medical Systems: Revenue ($bn) and Revenue Shares (%) by Segment, 2012
Table 5.10 Varian Medical Systems: Oncology Systems Revenue ($bn) and Revenue Shares (%)
by Segment, 2012
Table 5.11 Varian Medical Systems: Historical R&D Expenses ($m) and R&D Expenses as
Percentage of Revenue (%), 2010-2012
Table 5.12 Elekta: Net Sales ($bn) and Net Sales Shares (%) by Region, 2012
Table 6.1 The Prostate Cancer Therapeutics Market: Revenue ($bn) and Market Shares (%) by
Region, 2012
Table 6.2 The Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR
(%) by Region, 2012-2017
Table 6.3 The Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR
(%) by Region, 2017-2023
Table 6.4 The US Market: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023
Table 6.5 The EU5 Prostate Cancer Therapeutics National Markets: Revenue ($bn) and Market
Shares (%) by Country, 2012
Table 6.6 The EU5 Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), AGR (%),
CAGR (%) by Region, 2012-2017
Table 6.7 The EU5 Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), AGR (%),
CAGR (%) by Region, 2017-2023
Table 6.8 The German and French Markets: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-
2023

13. www.visiongain.com
Contents
Table 6.9 The UK Market: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023
Table 6.10 The Spanish Market: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023
Table 6.11 The Italian Market: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023
Table 6.12 The Japanese Market: Revenue Forecast ($bn), AGR (%) CAGR (%), 2012-2023
Table 6.13 The BRIC Prostate Cancer Therapeutics Market: Revenue ($m) and Global Market
Shares (%) by Country, 2012
Table 6.14 The BRIC Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%),
CAGR (%) by Country, 2012-2017
Table 6.15 The BRIC Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%),
CAGR (%) by Country, 2017-2023
Table 6.16 The Chinese Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023
Table 6.17 The Indian Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023
Table 6.18 The Russian Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023
Table 6.19 The Brazilian Market: Revenue Forecast ($m), AGR (%) CAGR (%), 2012-2023
Table 7.1 SWOT Analysis of the Prostate Cancer Therapeutics Market, 2013-2023
Table 9.1 Segments in the Prostate Cancer Therapeutics Market: Sales ($bn) in 2012, 2017,
2019 and 2023
Table 9.2 The Prostate Cancer Therapeutics Market by Leading Regional Markets: Sales ($bn) in
2012, 2017, 2019 and 2023
Table 9.3 Market Shares (%) of the Leading Regional Prostate Cancer Therapeutics Markets in
2012, 2017, 2019 and 2023

14. www.visiongain.com
Contents
Figure 2.1 Treatment Sequence for Prostate Cancer, 2013
Figure 3.1 The Global Prostate Cancer Therapeutics Market: Revenues ($bn) by Segment, 2012
Figure 3.2 The Global Prostate Cancer Therapeutics Market: Market Shares (%) by Segment,
2012
Figure 3.3 The Global Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-2017
Figure 3.4 The Global Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2017-2023
Figure 4.1 The Prostate Cancer Drugs Market: Revenue ($bn) by Leading Drugs, 2012
Figure 4.2 The Prostate Cancer Drugs Market: Market Shares (%) by Leading Drugs, 2012
Figure 4.3 The Prostate Cancer Drugs Market Forecast: Revenue ($bn), 2012-2017
Figure 4.4 The Prostate Cancer Drugs Market Forecast: Revenue ($bn), 2017-2023
Figure 4.5 Zytiga: Revenue Forecast ($bn), 2012-2023
Figure 4.6 Lupron: Revenue Forecast ($bn), 2012-2023
Figure 4.7 Zoladex: Revenue Forecast ($bn), 2012-2023
Figure 4.8 Casodex: Revenue Forecast ($bn), 2012-2023
Figure 4.9 Taxotere: Revenue Forecast ($bn), 2012-2023
Figure 4.10 Provenge: Revenue Forecast ($bn), 2012-2023
Figure 4.11 Jevtana: Revenue Forecast ($bn), 2012-2023
Figure 4.12 Xtandi: Revenue Forecast ($bn), 2012-2023
Figure 4.13 Johnson & Johnson: Revenue Shares (%) by Segment, 2012
Figure 4.14 Johnson & Johnson: Historical Revenue ($bn), Net Income ($bn) and Profit Margin
(%), 2007-2012
Figure 4.15 Johnson & Johnson: Pharmaceutical Revenue ($bn) by Segment, 2012
Figure 4.16 Johnson & Johnson: Pharmaceutical Revenue Shares (%) by Segment, 2012
List of Figures

15. www.visiongain.com
Contents
Figure 4.17 Johnson & Johnson: Pharmaceutical Segment Historical Revenue ($bn) by Region,
2010-2012
Figure 4.18 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($bn) and R&D
Expenses as Percentage of Segment Revenue (%), 2010-2012
Figure 4.19 AstraZeneca: Revenue ($bn) by Segment, 2012
Figure 4.20 AstraZeneca: Revenue Shares (%) by Segment, 2012
Figure 4.21 AstraZeneca: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of
Revenue (%), 2008-2012
Figure 4.22 Sanofi: Historical Revenue Performance ($bn), 2008-2012
Figure 4.23 Sanofi: Net Sales ($bn) by Segment, 2012
Figure 4.24 Sanofi: Net Sales Shares (%) by Segment, 2012
Figure 4.25 Sanofi: Net Sales Shares (%) by Region, 2012
Figure 4.26 Sanofi: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Revenue
(%), 2010-2012
Figure 5.1 The Prostate Cancer Devices Market: Revenue ($m) by Segment, 2012
Figure 5.2 The Prostate Cancer Devices Market: Market Shares (%) by Segment, 2012
Figure 5.3 The Prostate Cancer Devices Market Forecast: Revenue ($m), 2012-2023
Figure 5.4 The Brachytherapy Market Forecast: Revenue ($m), 2012-2023
Figure 5.5 The Radical Prostatectomy Market Forecast: Revenue ($m), 2012-2023
Figure 5.6 The External Beam Radiation Therapy Market Forecast: Revenue ($m), 2012-2023
Figure 5.7 The Cryotherapy Market Forecast: Revenue ($m), 2012-2023
Figure 5.8 The HIFU Market Forecast: Revenue ($m), 2012-2023
Figure 5.9 Varian Medical Systems: Revenue ($bn) by Segment, 2012
Figure 5.10 Varian Medical Systems: Revenue Shares (%) by Segment, 2012
Figure 5.11 Varian Medical Systems: Historical Revenue ($bn), 2008-2012

16. www.visiongain.com
Contents
Figure 5.12 Varian Medical Systems: Revenue Shares (%) by Region, 2012
Figure 5.13 Varian Medical Systems: Oncology Systems Revenue ($bn) by Segment, 2012
Figure 5.14 Varian Medical Systems: Oncology Systems Revenue Shares (%) by Segment, 2012
Figure 5.15 Varian Medical Systems: Oncology Systems Revenue Shares (%) by Region, 2012
Figure 5.16 Varian Medical Systems: Historical R&D Expenses ($m) and R&D Expenses as
Percentage of Revenue (%), 2010-2012
Figure 5.17 Elekta: Historical Net Sales ($bn), 2008-2012
Figure 5.18 Elekta: Net Sales Shares (%) by Region, 2012
Figure 6.1 The Prostate Cancer Therapeutics Market: Revenue ($bn) by Region, 2012
Figure 6.2 The Prostate Cancer Therapeutics Market: Market Shares (%) by Region, 2012
Figure 6.3 The US Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-2023
Figure 6.4 The EU5 Prostate Cancer Therapeutics National Markets: Revenue ($bn) by Country,
2012
Figure 6.5 The EU5 Prostate Cancer Therapeutics National Markets: Market Shares (%) by
Country, 2012
Figure 6.6 The EU5 Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-2023
Figure 6.7 The German and French Prostate Cancer Therapeutics Market Forecast: Revenue
($bn), 2012-2023
Figure 6.8 The UK Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-2023
Figure 6.9 The Spanish Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-
2023
Figure 6.10 The Italian Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-
2023
Figure 6.11 The Japanese Prostate Cancer Therapeutics Market Forecast: Revenue ($bn), 2012-
2023
Figure 6.12 The BRIC Prostate Cancer Therapeutics Market: Revenue ($m), by Country, 2012

17. www.visiongain.com
Contents
Figure 6.13 The BRIC Prostate Cancer Therapeutics Market: Global Market Shares (%) by
Country, 2012
Figure 6.14 The Chinese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), 2012-
2023
Figure 6.15 The Indian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), 2012-2023
Figure 6.16 The Russian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), 2012-
2023
Figure 6.17 The Brazilian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), 2012-
2023
Figure 7.1 Porter’s Five Force Analysis of the Prostate Cancer Therapeutics Market, 2013-2023
Figure 9.1 Prostate Cancer Therapeutics Market: Sales ($bn) in 2012, 2017, 2019 and 2023
Figure 9.2 The Prostate Cancer Therapeutics Market: Market Shares (%) by Region, 2023

18. www.visiongain.com
Contents
AbbVie
Accord Healthcare
Actavis, Inc.
Active Biotech AB
Aduro Biotech
Advanced Medical Isotope Corporation
Advantagene, Inc.
Agensys
American Cancer Society
Amgen
Antoni Van Leeuwenhoek Hospital
Aragon Pharmaceuticals
Astellas Pharma
AstraZeneca
Bavarian Nordic
Bayer HealthCare
Beckman Coulter, Inc.
Bellicum Pharmaceuticals, Inc.
BioSante Pharmaceuticals
Bostwick Laboratories
Bristol Myers Squibb
BTG plc
C.R. Bard, Inc.
Organisations Mentioned in This Report

19. www.visiongain.com
Contents
Calypso
Cancer Research UK
Cedars-Sinai Medical Centre
Celgene Corporation
Committee for Medicare and Medicaid Services
Computer Motion
Cougar Biotechnology
Dendreon Corporation
Dosch Pharmaceuticals Pvt Ltd
Ealing Hospital NHS Trust
EDAP TMS
Elekta
EMD Serono
European Association of Urology
European Medicines Agency (EMA)
European Partnership Action Against Cancer (EPAAC)
Exelixis
Food and Drug Administration (FDA)
Genentech (Roche)
Genfar Laboratories
GenomeDX Biosciences
Genomic Health, Inc.
Genzyme
GLOBOCAN

20. www.visiongain.com
Contents
Hologic, Inc.
Hospira Inc
Intuitive Surgical
Ipsen
Iris International
Italian National Health Service
Johnson & Johnson
Levine Cancer Institute
MacroGenics
MDxHealth
Medical College of Wisconsin
Medivation
Metabolon, Inc.
Metamark Genetics
Micromet (Amgen)
Mitomics, Inc.
Mylan Pharmaceuticals, Inc.
Myriad Genetics
National Cancer Institute (NCI)
National Epidemiological Centre
National Health Service (NHS)
National Institute of Clinical Excellence (NICE)
Newport Laboratories
NorthWest Biotherapeutics

21. www.visiongain.com
Contents
Nucletron
OncoGenex Pharmaceuticals
Oncura, Inc.
Opko Health, Inc.
Philips
Pluromed, Inc.
Princess Margaret Cancer Center
Progenics Pharmaceuticals, Inc.
Radon Ltd
Regeneron Pharmaceuticals, Inc.
Roche
Sandoz
Sanofi
Seattle Genetics
Siemens
SonaCare Medical
Sun Pharmaceuticals Ltd
Sunnybrook Health Sciences Centre
Synthon Pharmaceuticals, Inc.
Takeda Pharmaceutical Co Ltd
Teva
The Clinical Cancer Center at Froedtert
The Netherlands Cancer Institute
The University of Texas MS Anderson Centre

22. www.visiongain.com
Contents
Tokai Pharmaceuticals, Inc.
United Nations (UN)
University Medical Centre Utrecht
University of California
University of York
Varian Medical Systems
World Health Organisation
YCR Cancer Research
Zydus Pharmaceuticals

23. Page 56www.visiongain.com
The Prostate Cancer Therapeutics Market
2013-2023
4.5.3 Zoladex (AstraZeneca)
Zoladex is a luteinising hormone releasing hormone (LHRH) agonist that acts on the pituitary gland
in the brain to control the secretion of oestrogen and testosterone. It is classified as a hormone
therapy. As some breast cancers are caused by oestrogen and some prostrate cancers by
testosterone, modulating the amounts of the hormone in a patient can cause their tumours to
shrink. Zoladex is approved to treat prostate cancers and breast cancers. The drug is injected
subcutaneously every four weeks or as a longer acting preparation every 12 weeks.
4.5.3.1 Zoladex Sales, 2012
In 2012, Zoladex generated total revenue of $1.1bn, a decrease of 7.6% from 2011 sales figures of
$1.2bn. As mentioned earlier, Zoladex is indicated for both prostate and breast cancer. However,
the company does not provide an individual breakdown for the two indications. According to
visiongain estimates, Zoladex (for prostate cancer indication) generated revenue worth $0.6bn and
represented 12.7% of the total prostate cancer drugs market. Zoladex faces competition from
similar products like Eligard (Sanofi) and Lupron (AbbVie). Zoladex’s patent will expire in 2021 in
both the US and Europe. After that, visiongain expects Zoladex to come under significant pressure
from a generic version.
Figure 4.6 Lupron: Revenue Forecast ($bn), 2012-2023
0.7
0.7
0.7
0.6
0.6
0.6
0.5
0.4
0.4
0.3
0.3
0.3
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
Revenue($bn)
Year
Source: Visiongain 2013

24. Page 75www.visiongain.com
The Prostate Cancer Therapeutics Market
2013-2023
4.7.14 OGX-427 (OncoGenex Pharmaceuticals)
OGX-427 is a second generation once weekly intravenous experimental drug, which inhibits the
production of heat shock protein 27 (Hsp27). Hsp27 is a cell survival protein found at elevated
levels in many human cancers. There are currently two phase II investigational programs (Pacific
and OGX-427-PR01) for OGX-427 which aims to demonstrate the drug’s ability to inhibit Hsp27 in
prostate cancer patients.
4.7.15 ARN-509 (Johnson & Johnson)
ARN-509 is being developed on the success of enzalutamide. Like enzalutamide, this drug works
through competitive androgen receptor inhibition that is purely antagonistic. It has also been shown
to reduce efficiency of nuclear translocation of the androgen receptor and impairs androgen
receptor binding to androgen-response element of the DNA. The preclinical evidence for ARN-509
as a promising therapeutic agent has led to the opening of the phase II trial evaluating the
efficiency of the drug with various CRPC states. The results are expected to be generated by 2018.
As a result, it will not be a major competitor to Xtandi in the next 7-8 years.
Table 4.15 shows key drugs in phase I development in the prostate cancer drugs market. These
drugs are profiled below.
Table 4.15 Key Drugs in Phase I Clinical Trials, 2013
Drug Company Type
MGAH22 Macrogenics
Fc-optimised monoclonal antibody (mAb) that targets
HER2
RG7450 Roche Humanised mAb targeting STEAP1
ASG-5ME Agensys/Seattle Genetics
ASG-5ME is an antibody-drug conjugate (ADC) targeting
the SLC44A4 antigen
BAY2010112 Bayer Pharmaceuticals
Novel BiTE antibody that is bispecific for prostate-
specific membrane antigen (PSMA) and the CD3 epsilon
subunit of the T cell receptor complex
GDC-0068 Roche Inhibitor of the serine/threonine protein kinase, Akt
BPX-101 Bellicum Pharmaceuticals Novel drug activated dendritic cell vaccine
Source: Visiongain 2013

25. Page 82www.visiongain.com
The Prostate Cancer Therapeutics Market
2013-2023
4.8.1.3 Pharmaceutical Segment R&D Performance Analysis, 2012
The total R&D spending in the pharmaceutical segment in 2012 was $5.4bn, which represented
21.2% of the segment revenue. The expenditure in R&D has increased over the years, with a jump
of $1.0bn from 2010 to 2012. However, the R&D expenses as percentage of net sales has
remained almost consistent as the net sales have increased over the years. Table 4.19 and Figure
4.18 show the historical R&D expenses ($m) and R&D expenses as percentage of segment
revenue (%) from 2010-2012.
Table 4.19 Johnson & Johnson: Historical
Pharmaceutical R&D Expenses ($bn) and R&D Expenses
as Percentage of Segment Revenue (%), 2010-2012
Year R&D Expenses ($bn)
Percentage of
Segment Revenue (%)
2010 4.4 19.8
2011 5.1 21.1
2012 5.4 21.2
Figure 4.18 Johnson & Johnson: Historical Pharmaceutical R&D Expenses
($bn) and R&D Expenses as Percentage of Segment Revenue (%), 2010-2012
19
19.5
20
20.5
21
21.5
0.0
1.0
2.0
3.0
4.0
5.0
6.0
2010 2011 2012
PercentageofSegmentRevenue(%)
R&DExpenses($bn)
Year
Source: J&J2013; Visiongain 2013
Source: J&J2013; Visiongain 2013